Is BPC-157 Legal in Australia? 2026 Guide

Is BPC-157 legal in Australia?

The short answer is that BPC-157 is not an approved or registered medicine in Australia, and as of 1 June 2024 it is listed as a Schedule 4 (Prescription Only Medicine) substance under the Poisons Standard. That means it sits inside a regulated framework rather than being an open, freely available consumer product. There is no BPC-157 product entered on the Australian Register of Therapeutic Goods (ARTG) for any use.

In practice, this creates an important distinction. BPC-157 supplied as a laboratory reference material for research use only is a different thing from a therapeutic good marketed for people. On the Pepology store, BPC-157 and related compounds are handled strictly as research-use-only laboratory materials. They are not approved medicines, they are not sold for human or animal use, and no therapeutic outcome is claimed or implied anywhere.

The rest of this guide explains the TGA framework in plain terms, what the research-use-only designation actually means, how scheduling and the Poisons Standard work, and the due-diligence steps a careful buyer can take before purchasing any research compound in Australia.

What the TGA framework actually covers

The Therapeutic Goods Administration (TGA) is the national regulator for medicines and therapeutic goods in Australia. Its remit is anything represented, marketed, or supplied for a therapeutic purpose in people. A therapeutic purpose broadly includes preventing, diagnosing, or influencing a disease, ailment, or physiological process in humans.

Two TGA mechanisms matter most when you are trying to understand a compound like BPC-157. The first is the Australian Register of Therapeutic Goods, or ARTG. The second is the Poisons Standard, also known as the SUSMP.

The key takeaway is that a substance can be regulated and restricted without ever being an approved medicine. BPC-157 is exactly that situation. It carries scheduling controls, yet there is no registered therapeutic product behind it.

• The Australian Register of Therapeutic Goods (ARTG). This is the public list of medicines and devices that have been assessed and permitted to be supplied in Australia for a stated therapeutic use. BPC-157 is not on it.
• The Poisons Standard, also called the SUSMP. This document assigns substances to schedules that set the controls on how they can be accessed. BPC-157 was added to Schedule 4 of this standard.

How scheduling and Schedule 4 work

The Poisons Standard sorts substances into schedules from Schedule 2 through to Schedule 10, each with its own level of control. The higher the schedule number, the tighter the access controls, generally speaking.

Schedule 4 is the Prescription Only Medicine category. Substances placed in Schedule 4 are those the scheduling delegate has determined should be accessed only through a valid prescription from an authorised Australian health practitioner, or through specific regulated pathways.

On 1 June 2024, following a public consultation and a final decision published in May 2024, BPC-157 was entered into Schedule 4. The decision also created a related Appendix D entry. Before that date, BPC-157 was unscheduled, which is part of why older information online can be inconsistent. Any article or product page that still describes BPC-157 as simply unscheduled or unrestricted in Australia is out of date on this point.

What research use only actually means

Research use only is a labelling and supply designation. It indicates that a material is intended for laboratory research and experimental use, and that it is not supplied as a medicine, food, cosmetic, or consumer product for people or animals. A research-use-only material is not evaluated or approved for human or animal use, and no safety or efficacy for such use is claimed.

It is important to be precise about what this designation does and does not do.

This is why reputable research suppliers keep their framing strictly to laboratory use and avoid any dosing, protocol, or outcome language. If you want a deeper walk-through of this category and how to assess suppliers, see our research peptides Australia buyers guide.

• It describes the intended use and the basis on which the material is supplied, namely laboratory research.
• It signals that the material has not been assessed by the TGA as a therapeutic good and is not on the ARTG.
• It does not override the Poisons Standard. Scheduling applies to the substance itself, so a research-use-only label does not change the fact that BPC-157 is listed in Schedule 4.
• It is not a loophole for human or animal use. Representing a research material for use in people would move it into the therapeutic-goods framework and the controls that come with it.

research peptides Australia buyers guide

Labelling and documentation to expect

For a research-use-only compound, the documentation and labelling are the substance of the product. There is no therapeutic claim to rely on, so the identity, purity, and provenance of the material are what matter. A careful buyer looks for clear, verifiable paperwork rather than marketing language.

Reasonable things to look for are set out below.

Pepology publishes independent Novagen laboratory certificates on a public register, so a batch can be checked against an external record rather than taken on trust. If you are not sure how to interpret these documents, our guide on how to read a peptide certificate of analysis breaks down each section in plain language.

• A clear research-use-only statement and explicit wording that the material is not for human or animal use.
• The compound name, any identifier or batch or lot number, and the stated nominal quantity.
• An independent certificate of analysis (CoA) that reports identity and purity for the specific batch.
• A way to verify that certificate against a public record rather than a PDF emailed on request.

how to read a peptide certificate of analysis

Buyer due diligence before you purchase

Because BPC-157 is scheduled and is not an approved medicine, due diligence is about understanding the regulatory position and verifying what you are actually buying as a research material. A methodical approach protects you from misinformation and from low-quality or misrepresented products.

A practical checklist is set out below.

For more on independent verification and what purity figures really represent, see our articles on third-party tested peptides in Australia and what pure peptides in Australia actually means. These cover the testing side in detail without any human-use framing.

• Confirm the current scheduling position yourself. Treat BPC-157 as a Schedule 4 substance and check the TGA Poisons Standard directly rather than relying on old blog posts.
• Read the supplier framing carefully. Research-use-only suppliers should never provide human dosing, protocols, or therapeutic claims. Marketing that promises outcomes is a red flag.
• Insist on batch-specific documentation. A generic CoA that is not tied to the lot you receive tells you very little.
• Verify independently. Cross-check the certificate against a public register where possible.
• Understand purity language. Terms like pure and high purity have specific meanings in analytical testing.

third-party tested peptides in Australia what pure peptides in Australia actually means

Importation and the WADA position

Two further points are worth noting for context. First, the original scheduling proposal followed a number of TGA referrals relating to importation of BPC-157, and personal importation of a Schedule 4 substance without an appropriate pathway is not a straightforward consumer transaction. Anyone considering importation should understand that scheduling applies regardless of how a product is labelled.

Second, BPC-157 has been listed by the World Anti-Doping Agency (WADA) as a prohibited substance under category S0 since 2022, which is relevant to anyone in a sport that operates under anti-doping rules. Australian anti-doping follows the WADA list. This is a factual status point, not a comment on any use.

The bottom line for 2026

As of 2026, the accurate position is straightforward. BPC-157 is not an approved or registered medicine in Australia, and it is listed in Schedule 4 of the Poisons Standard as a Prescription Only Medicine, a change that took effect on 1 June 2024. There is no ARTG-registered BPC-157 product.

Separately from all of that, BPC-157 can be supplied as a research-use-only laboratory material, meaning it is not for human or animal use and carries no therapeutic claims. Pepology treats it strictly on that basis. The research-use-only designation describes the intended laboratory use and the documentation standard, and it does not change the scheduling of the substance itself.

If you are researching this compound, focus on verifiable facts: current scheduling, batch-level certificates of analysis, and independent verification. You can review the compound entry itself on our BPC-157 page, and use the public register to confirm a batch before you rely on any documentation.

BPC-157 page confirm a batch before you rely on any documentation